Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
===== MeSH D08.811.277.656 – peptide hydrolases (EC 3.4) ===== MeSH D08.811.277.656.149 – atp-dependent proteases MeSH D08.811.277.656.149.200 – endopeptidase clp MeSH D08.811.277.656.149.500 – protease la MeSH D08.811.277.656.300 – endopeptidases MeSH D08.811.277.656.300.066 – aspartic endopeptidases MeSH D08.811.277.656.300.066.180 – cathepsin d MeSH D08.811.277.656.300.066.185 – cathepsin e MeSH D08.811.277.656.300.066.200 – chymosin MeSH D08.811.277.656.300.066.340 – HIV protease MeSH D08.811.277.656.300.066.700 – pepsin a MeSH D08.811.277.656.300.066.780 – renin MeSH D08.811.277.656.300.099 – brinolase MeSH D08.811.277.656.300.133 – cathepsins MeSH D08.811.277.656.300.133.062 – carboxypeptidase c MeSH D08.811.277.656.300.133.125 – cathepsin b MeSH D08.811.277.656.300.133.187 – cathepsin d MeSH D08.811.277.656.300.133.250 – cathepsin e MeSH D08.811.277.656.300.133.375 – dipeptidyl peptidase i MeSH D08.811.277.656.300.174 – coagulase MeSH D08.811.277.656.300.215 – cysteine endopeptidases MeSH D08.811.277.656.300.215.096 – bromelains MeSH D08.811.277.656.300.215.120 – calpain MeSH D08.811.277.656.300.215.126 – caspases MeSH D08.811.277.656.300.215.126.200 – caspase 1 MeSH D08.811.277.656.300.215.133 – cathepsin b MeSH D08.811.277.656.300.215.160 – chymopapain MeSH D08.811.277.656.300.215.350 – ficain MeSH D08.811.277.656.300.215.585 – papain MeSH D08.811.277.656.300.480 – metalloendopeptidases MeSH D08.811.277.656.300.480.205 – collagenases MeSH D08.811.277.656.300.480.205.352 – gelatinase a MeSH D08.811.277.656.300.480.205.360 – gelatinase b MeSH D08.811.277.656.300.480.205.410 – interstitial collagenase MeSH D08.811.277.656.300.480.205.500 – microbial collagenase MeSH D08.811.277.656.300.480.205.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.252 – gelatinases MeSH D08.811.277.656.300.480.252.420 – gelatinase a MeSH D08.811.277.656.300.480.252.445 – gelatinase b MeSH D08.811.277.656.300.480.300 – insulysin MeSH D08.811.277.656.300.480.452 – lysostaphin MeSH D08.811.277.656.300.480.525 – matrix metalloproteinases MeSH D08.811.277.656.300.480.525.352 – gelatinase a MeSH D08.811.277.656.300.480.525.360 – gelatinase b MeSH D08.811.277.656.300.480.525.451 – interstitial collagenase MeSH D08.811.277.656.300.480.525.505 – matrilysin MeSH D08.811.277.656.300.480.525.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.525.810 – stromelysin 1 MeSH D08.811.277.656.300.480.600 – neprilysin MeSH D08.811.277.656.300.480.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.300.480.664 – procollagen n-endopeptidase MeSH D08.811.277.656.300.480.680 – pronase MeSH D08.811.277.656.300.480.827 – thermolysin MeSH D08.811.277.656.300.760 – serine endopeptidases MeSH D08.811.277.656.300.760.030 – acrosin MeSH D08.811.277.656.300.760.176 – chymotrypsin MeSH D08.811.277.656.300.760.198 – complement factor b MeSH D08.811.277.656.300.760.200 – complement factor d MeSH D08.811.277.656.300.760.210 – complement factor i MeSH D08.811.277.656.300.760.228 – endopeptidase clp MeSH D08.811.277.656.300.760.247 – endopeptidase k MeSH D08.811.277.656.300.760.284 – enteropeptidase MeSH D08.811.277.656.300.760.300 – factor viia MeSH D08.811.277.656.300.760.310 – factor ixa MeSH D08.811.277.656.300.760.315 – factor xa MeSH D08.811.277.656.300.760.320 – factor xia MeSH D08.811.277.656.300.760.324 – factor xiia MeSH D08.811.277.656.300.760.353 – furin MeSH D08.811.277.656.300.760.442 – kallikreins MeSH D08.811.277.656.300.760.442.700 – plasma kallikrein MeSH D08.811.277.656.300.760.442.725 – prekallikrein MeSH D08.811.277.656.300.760.442.750 – prostate-specific antigen MeSH D08.811.277.656.300.760.442.875 – tissue kallikreins MeSH D08.811.277.656.300.760.501 – mannose-binding protein-associated serine proteases MeSH D08.811.277.656.300.760.560 – pancreatic elastase MeSH D08.811.277.656.300.760.560.500 – leukocyte elastase MeSH D08.811.277.656.300.760.625 – plasmin MeSH D08.811.277.656.300.760.635 – plasminogen activators MeSH D08.811.277.656.300.760.635.075 – anistreplase MeSH D08.811.277.656.300.760.640 – proprotein convertase 1 MeSH D08.811.277.656.300.760.646 – proprotein convertase 2 MeSH D08.811.277.656.300.760.648 – proprotein convertase 5 MeSH D08.811.277.656.300.760.680 – pronase MeSH D08.811.277.656.300.760.733 – protease la MeSH D08.811.277.656.300.760.787 – subtilisins MeSH D08.811.277.656.300.760.787.805 – subtilisin MeSH D08.811.277.656.300.760.855 – thrombin MeSH D08.811.277.656.300.760.875 – tissue plasminogen activator MeSH D08.811.277.656.300.760.895 – trypsin MeSH D08.811.277.656.300.760.910 – urinary plasminogen activator MeSH D08.811.277.656.300.760.955 – venombin a MeSH D08.811.277.656.300.760.955.060 – ancrod MeSH D08.811.277.656.300.760.955.135 – batroxobin MeSH D08.811.277.656.300.775 – streptokinase MeSH D08.811.277.656.300.775.075 – anistreplase MeSH D08.811.277.656.300.775.900 – streptodornase and streptokinase MeSH D08.811.277.656.350 – exopeptidases MeSH D08.811.277.656.350.100 – aminopeptidases MeSH D08.811.277.656.350.100.150 – amino acid naphthylamidases MeSH D08.811.277.656.350.100.150.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.160 – antigens, cd13 MeSH D08.811.277.656.350.100.235 – cystinyl aminopeptidase MeSH D08.811.277.656.350.100.373 – glutamyl aminopeptidase MeSH D08.811.277.656.350.100.511 – leucyl aminopeptidase MeSH D08.811.277.656.350.100.511.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.755 – pyroglutamyl-peptidase I MeSH D08.811.277.656.350.245 – carboxypeptidases MeSH D08.811.277.656.350.245.055 – carboxypeptidases A MeSH D08.811.277.656.350.245.083 – carboxypeptidase B MeSH D08.811.277.656.350.245.111 – carboxypeptidase C MeSH D08.811.277.656.350.245.167 – carboxypeptidase H MeSH D08.811.277.656.350.245.224 – carboxypeptidase U MeSH D08.811.277.656.350.245.252 – Serine-type D-Ala-D-Ala carboxypeptidase MeSH D08.811.277.656.350.245.280 – gamma-glutamyl hydrolase MeSH D08.811.277.656.350.245.400 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.245.450 – lysine carboxypeptidase MeSH D08.811.277.656.350.245.500 – muramoylpentapeptide carboxypeptidase MeSH D08.811.277.656.350.297 – dipeptidases MeSH D08.811.277.656.350.350 – dipeptidyl peptidases MeSH D08.811.277.656.350.350.126 – antigens, cd26 MeSH D08.811.277.656.350.350.375 – dipeptidyl peptidase i MeSH D08.811.277.656.350.555 – metalloexopeptidases MeSH D08.811.277.656.350.555.100 – antigens, cd13 MeSH D08.811.277.656.350.555.200 – carboxypeptidase b MeSH D08.811.277.656.350.555.250 – carboxypeptidase h MeSH D08.811.277.656.350.555.300 – carboxypeptidase u MeSH D08.811.277.656.350.555.350 – carboxypeptidases a MeSH D08.811.277.656.350.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.350.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.350.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.350.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.350.700 – peptidyl-dipeptidase a MeSH D08.811.277.656.675 – metalloproteases MeSH D08.811.277.656.675.374 – metalloendopeptidases MeSH D08.811.277.656.675.374.102 – adam proteins MeSH D08.811.277.656.675.374.205 – collagenases MeSH D08.811.277.656.675.374.205.352 – gelatinase a MeSH D08.811.277.656.675.374.205.360 – gelatinase b MeSH D08.811.277.656.675.374.205.410 – interstitial collagenase MeSH D08.811.277.656.675.374.205.500 – microbial collagenase MeSH D08.811.277.656.675.374.205.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.252 – gelatinases MeSH D08.811.277.656.675.374.252.420 – gelatinase a MeSH D08.811.277.656.675.374.252.445 – gelatinase b MeSH D08.811.277.656.675.374.300 – insulysin MeSH D08.811.277.656.675.374.452 – lysostaphin MeSH D08.811.277.656.675.374.525 – matrix metalloproteinases MeSH D08.811.277.656.675.374.525.352 – gelatinase a MeSH D08.811.277.656.675.374.525.360 – gelatinase b MeSH D08.811.277.656.675.374.525.451 – interstitial collagenase MeSH D08.811.277.656.675.374.525.505 – matrilysin MeSH D08.811.277.656.675.374.525.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.525.810 – stromelysin 1 MeSH D08.811.277.656.675.374.600 – neprilysin MeSH D08.811.277.656.675.374.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.675.374.664 – procollagen n-endopeptidase MeSH D08.811.277.656.675.374.680 – pronase MeSH D08.811.277.656.675.374.827 – thermolysin MeSH D08.811.277.656.675.555 – metalloexopeptidases MeSH D08.811.277.656.675.555.100 – antigens, cd13 MeSH D08.811.277.656.675.555.200 – carboxypeptidase b MeSH D08.811.277.656.675.555.250 – carboxypeptidase h MeSH D08.811.277.656.675.555.300 – carboxypeptidase u MeSH D08.811.277.656.675.555.350 – carboxypeptidases a MeSH D08.811.277.656.675.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.675.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.675.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.675.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.675.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.675.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.837 – proprotein convertases MeSH D08.811.277.656.837.124 – carboxypeptidase h MeSH D08.811.277.656.837.186 – carboxypeptidase u MeSH D08.811.277.656.837.249 – furin MeSH D08.811.277.656.837.500 – proprotein convertase 1 MeSH D08.811.277.656.837.562 – proprotein convertase 2 MeSH D08.811.277.656.837.625 – proprotein convertase 5 MeSH D08.811.277.656.837.750 – renin MeSH D08.811.277.656.918 – proteasome endopeptidase complex
Following the release and favorable reviews of Last Days Here, Liebling and Pentagram experienced a significant resurgence in popularity. The documentary won multiple awards, including the Grand Jury Prize at the Independent Film Festival of Boston and Best Music Documentary at the International Documentary Film Festival Amsterdam. This renewed attention revitalized Pentagram's career, leading to international tours. Releasing a new album around the same time the documentary was published accelerated the band's resurgence. Liebling, alongside longtime collaborator Victor Griffin, returned to the studio for Last Rites, which was released in April 2011. This marked Griffin's first studio work with Pentagram in over 15 years. At the time, Liebling noted that he had written the music and lyrics for about half of the band's earlier albums, "while 30–40% were collaborations with musicians, typically guitar players". Regarding his songwriting approach for the "Last Rites", he said: "I just write the lyrics nowadays. I ran out of music. I wrote 450 songs in 30 years." In 2011, Metal Blade Records announced Pentagram's return to live performances, which included an appearance at South by Southwest and a European tour that began at the Roadburn Festival in the Netherlands. Liebling embarked on extensive touring across North America and Europe with Pentagram in the following years. However, the band continued to experience frequent lineup changes. Pentagram maintained its momentum with the release of the album Curious Volume on August 21, 2015.
When newly opened, Viola flowers may be used to decorate salads or in stuffings for poultry or fish. Soufflés, cream, and similar desserts can be flavoured with essence of Viola flowers. The young leaves are edible raw or cooked as a mild-tasting leaf vegetable. The flowers and leaves of the cultivar 'Rebecca', one of the Violetta violets, have a distinct vanilla flavor with hints of wintergreen. The pungent perfume of some varieties of V. odorata adds inimitable sweetness to desserts, fruit salads, and teas while the mild pea flavor of V. tricolor combines equally well with sweet or savory foods, like grilled meats and steamed vegetables. The heart-shaped leaves of V. odorata provide a free source of greens throughout a long growing season, while the petals are used for fragrant flavoring in milk puddings and ice cream or in salads and as garnishes. A candied violet or crystallized violet is a flower, usually of Viola odorata, preserved by a coating of egg white and crystallised sugar. Alternatively, hot syrup is poured over the fresh flower (or the flower is immersed in the syrup) and stirred until the sugar recrystallizes and has dried. This method is still used for rose petals and was applied to orange flowers in the past (when almonds or orange peel are treated this way they are called pralines). Candied violets are still made commercially in Toulouse, France, where they are known as violettes de Toulouse. They are used as decorating cakes or trifles or included in aromatic desserts.
Sources: en.wikipedia.org
Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia. It is often a complication of an existing chronic inflammatory disease such as rheumatoid arthritis, dermatomyositis, or it can be a side effect of certain medications such as amiodarone. COP was first described by Gary Epler in 1985. The clinical features and radiological imaging resemble infectious pneumonia. However, diagnosis is suspected after there is no response to multiple antibiotics, and blood and sputum cultures are negative for organisms.
== Other major examples == The cytochrome P450 isozymes play important roles in metabolism and steroidogenesis. The multiple forms of phosphodiesterase also play major roles in various biological processes. Although more than one form of these enzymes have been found in individual cells, these isoforms of the enzyme are unequally distributed in the various cells of an organism. From the clinical standpoint they have been found to be selectively activated and inhibited, an observation which has led to their use in therapy.
== Education == Macor trained as an organic chemist. Macor received his B.S. in chemistry from the University of Notre Dame and his Ph.D. in chemistry from Princeton University in 1986, where he worked under Edward C. Taylor.
== Toxicity == Several typical mechanisms underlying graphene (oxide) nanomaterial's toxicity have been revealed, for instance, physical destruction, oxidative stress, DNA damage, inflammatory response, apoptosis, autophagy, and necrosis. In these mechanisms, toll-like receptors (TLR), transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α) dependent-pathways are involved in the signalling pathway network, and oxidative stress plays a crucial role in these pathways. Many experiments have shown that graphene (oxide) nanomaterials have toxic side effects in many biological applications, but more in-depth study of toxicity mechanisms is needed. According to the USA FDA, graphene, graphene oxide, and reduced graphene oxide elicit toxic effects both in vitro and in vivo. Graphene-family nanomaterials (GFN) are not approved by the USA FDA for human consumption.
Sources: en.wikipedia.org
During the lockdown Gavin suggested, 'Why don't we record these things so we've at least got studio recordings of this material?' That doesn't mean we're going to make a new album or it's ever gonna come out, but we have started this process." In a November 2024 interview with Louder Sound, Jakszyk was questioned about the band's future and mentioned the possibility of new studio recordings being released, stating: "The honest answer is, you'll have to ask Robert. It's all in his hands. He's retired a million times before, but he is 78. One of the things we have been doing of late is recording studio versions of the new material [only previously played live]. We've used the live recordings as a template, and I've done guitars, overdubs and backing vocals. Whether that comes out as a King Crimson album or whether it lies in the vaults, I don't know." Eight months later, in a July 2025 interview with Goldmine magazine, Jakszyk stated that "as we speak, we're doing a King Crimson studio album" and confirmed that it featured the most recent band line-up. He cautioned "when that will come out and what format or how — that's beyond my brief. But yeah, we've been doing it piecemeal, and then a couple of months ago, the management said, 'Can we?' So, yeah. I've been recording that with a view to it coming out in some format at some point. But who knows when?... There also are future plans for some live film of us playing in various places. There's an ongoing thread.
First, in a series of Commission decisions, Google and Amazon were fined for competition violations. In the Google Shopping case, the Commission fined Google €2.4 billion for giving preference to its own shopping results over others in Google's search, leading to huge increases in traffic for Google over rivals. In the Google Android case the Commission fined Alphabet Inc (by then Google's rebranded parent name) €4.34 billion, or 4.5% of worldwide turnover, for paying phone manufacturers to pre-install its apps, such as Google search or Chrome, as a condition to license its app marketplace Google Play. In the Google AdSense case, the Commission fined Google €1.49 billion for stopping third-party websites displaying their adverts in Google's embedded search widgets, given that it was dominant in the ad market, and unfairly excluding competitors from results. In the Amazon Marketplace case an investigation for abuse of dominant position was launched for Amazon using other traders' data to benefit its own retail business, and preferencing itself in its "Buy Box" and in access to "Prime" seller status. This was settled after Amazon committed in 2022 "not to use non-public data relating to, or derived from, the independent sellers' activities on its marketplace, for its retail business", and to not discriminate against third parties in its Buy Box and Prime services. The Digital Markets Act codifies many of these standards.
=== Science and technology === The National Science and Technology Council (CCT) and the National Fund for Scientific and Technological Development were also restructured, with the Minister of Science, Technology and Innovation Luciana Santos saying that the government would increase investments in that area. On 16 February, Lula announced yet another readjustment in the value of scholarships during an event in the Planalto Palace. and stated that "in this government it is forbidden to treat money that goes to education, scholarships, or healthcare as an expense." He later restructured the National Council for Science and Technology (CCT) and restored the National Fund for Scientific and Technological Development (FNDCT). The minister of science, technology and innovation, Luciana Santos, stated that investment in the area is a priority for the government.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.